Document is current
Any future updates will be listed below
-
Authors
Sahai, Erik https://orcid.org/0000-0002-3932-5086
Astsaturov, Igor https://orcid.org/0000-0002-8613-1890
Cukierman, Edna
DeNardo, David G. https://orcid.org/0000-0002-3655-5783
Egeblad, Mikala
Evans, Ronald M.
Fearon, Douglas
Greten, Florian R. https://orcid.org/0000-0002-3928-6080
Hingorani, Sunil R.
Hunter, Tony
Hynes, Richard O.
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
Janowitz, Tobias
Jorgensen, Claus
Kimmelman, Alec C.
Kolonin, Mikhail G.
Maki, Robert G.
Powers, R. Scott
Puré, Ellen
Ramirez, Daniel C.
Scherz-Shouval, Ruth
Sherman, Mara H.
Stewart, Sheila https://orcid.org/0000-0002-2260-9576
Tlsty, Thea D.
Tuveson, David A.
Watt, Fiona M. https://orcid.org/0000-0001-9151-5154
Weaver, Valerie
Weeraratna, Ashani T.
Werb, Zena https://orcid.org/0000-0002-6525-3872
- License Information
-
More Information
Article History
Accepted: 19 December 2019
First Online: 24 January 2020
Competing Interests
: S.R.H. is a consultant for Halozyme Therapeutics, from which the Fred Hutchinson Cancer Research Center receives research funding. R.K.J. received honorarium from Amgen, consultant fees from Chugai, Merck, Ophthotech, Pfizer, SPARC, SynDevRx and XTuit, owns equity in Enlight, Ophthotech and SynDevRx and serves on the boards of trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. Neither any reagent nor any funding from these organizations was used in this study. A.C.K. has financial interests in Vescor Therapeutics, is an inventor named on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach and the autophagic control of iron metabolism, is on the Scientific Advisory Board of Rafael Pharmaceuticals and has been a consultant for Deciphera Pharmaceuticals. R.G.M. receives consulting fees from Bayer, Deciphera, Karyopharm, Springworks, the American Society of Clinical Oncology and UptoDate. E.P. receives research funds in the form of a sponsored research agreement from TMUNITY and a collaborative research agreement from Boehringer Ingelheim; prior funding was provided by Novartis. D.A.T. has received commercial research grants from Fibrogen and ONO, has ownership interest (including stock, patents and so on) in Leap Therapeutics and Surface Oncology and is a consultant/advisory board member for Leap Oncology, Surface Oncology, Cygnal and Merck. D.A.T. is Director and Chief Scientist of the Lustgarten Foundation, a designated laboratory of pancreatic cancer research. F.M.W. is currently on secondment as Executive Chair of the UK Medical Research Council. Z.W. is on the Advisory Board of Maverick Therapeutics. E.S., I.A., E.C., D.D., M.E., R.M.E., D.F., F.R.G., T.H., R.O.H., T.J., C.J., M.G.K, R.S.P., D.C.R., R.S-S., M.H.S., S.S., T.D.T., V.W. and A.T.W. declare no competing interests.
